预约演示
更新于：2026-02-27
Perindopril Erbumine
特丁胺培哚普利
更新于：2026-02-27
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H43N3O5 |
InChIKeyIYNMDWMQHSMDDE-MHXJNQAMSA-N |
CAS号107133-36-8 |
关联
99
项与 特丁胺培哚普利 相关的临床试验CTR20252825
培哚普利叔丁胺片在空腹和餐后条件下的人体生物等效性试验
CTR20244761
培哚普利叔丁胺片在健康参与者中空腹条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验
ACTRN12624000648527
FAN Trial: A randomised controlled open label trial assessing the effect of perindopril erbumine on Fontan-Associated Nephropathy in adults and children 5 years or older.
100 项与 特丁胺培哚普利 相关的临床结果
登录后查看更多信息
100 项与 特丁胺培哚普利 相关的转化医学
登录后查看更多信息
100 项与 特丁胺培哚普利 相关的专利（医药）
登录后查看更多信息
1,258
项与 特丁胺培哚普利 相关的文献（医药）2026-03-16SPECTROSCOPY LETTERS
Ecological and human health risk assessment of pharmaceutical compounds in the Indian river ecosystem
作者: Ruby, Ruby ; Giri, Arup ; Dimple, Dimple ; Jyoti, Jyoti
Pharmaceutical compounds release into aquatic ecosystem has become a critical problem because they can harm aquatic organisms and humans. Humans may have serious effects due to presence of phamaceuticals in drinking water.This study aims to analyze pharmaceutical compound ecol. and human health risk assessments in thirteen Indian River ecosystems. In this study, various pharmaceuticals, such as ciprofloxacin, norfloxacin, aspirin, carbamazepine, caffeine, and ibuprofen, were detected in different river ecosystems across India. This study aims to analyze the concentrations of pharmaceutical compounds, including the risk quotient (RQ), while performing an ecol. risk assessment.For human health risk assessment, metrics such as acceptable daily intake (ADI) and the risk quotient were employed to assess human health (RQH). The health risk models revealed that the Sirsa River posed significant ecol. threats because RQ greater than 1, whereas the other rivers presented moderate risks. Children were found to be more vulnerable to pharmaceutical intake, and all the rivers presented RQH values exceeding 1 for adults, underscoring serious health concerns.This study will help categorize pharmaceutical compounds and analyze the ecol. and human health risks to water systems. This study provides key insights for policymakers and public health efforts to address pharmaceutical pollution in Indian rivers. It also aligns with the UN Sustainable Development Goals, particularly SDGs 6 and 12.
2025-12-01HYPERTENSION RESEARCH
Risk of liver dysfunction with ACE inhibitors based on real-world data from the MID-NET® in Japan
Article
作者: Matsunaga, Yusuke ; Tanaka, Taihei ; Kajiyama, Kazuhiro ; Ando, Takashi ; Maruyama, Hotaka ; Tanaka, Ayumi ; Ishiguro, Chieko ; Kinoshita, Yuki ; Kohama, Mei ; Horiuchi, Naoya ; Nonaka, Takahiro ; Uyama, Yoshiaki
Abstract:
Warnings about liver dysfunction in Japanese package inserts vary among angiotensin-converting enzyme (ACE) inhibitors, and risk assessment of liver dysfunction with ACE inhibitors has been limited. To evaluate the risk of liver dysfunction among patients prescribed ACE inhibitors available in Japan, we conducted this study based on the real-world data from MID-NET
®
. We identified patients who were newly prescribed ACE inhibitors between January 1, 2009 and December 31, 2019 and excluded patients with liver dysfunction before the first prescription of ACE inhibitors. To compare the risk of liver dysfunction between the control group (enalapril maleate) and each exposure group, a pairwise Cox proportional hazards model was employed to estimate the hazard ratio (HR) adjusted by inverse probability weighting based on the high-dimensional propensity score. A total of 29,817 patients were identified for analysis in the cohort. Compared with the control group, the HRs (95% confidence interval) were 1.37(0.79–2.38) for captopril, 0.71(0.33–1.54) for alacepril, 0.72(0.55–0.93) for imidapril hydrochloride, 1.08(0.86–1.34) for perindopril erbumine, and 0.69(0.52–0.91) for lisinopril hydrate. The risk of liver dysfunction with ACE inhibitors is unlikely to be a class-effect. Although continuous safety monitoring is necessary for promoting proper use of ACE inhibitors, the results indicate that no additional safety measures are currently required for ACE inhibitors that do not carry a liver dysfunction-related warning in Japan.
2025-04-01JOURNAL OF PHARMACEUTICAL SCIENCES
Optimization of HPLC method for determination of Abraham solvation parameters of pharmaceuticals
Article
作者: Knašienė, Birutė ; Sadaunykas, Audrius ; Sazonovas, Andrius ; Naujalis, Evaldas ; Lanevskij, Kiril ; Balčiūnas, Simonas
Abraham solvation equation (Absolv) is a popular and well-established approach for modeling solute partitioning between phases of different polarity, which finds its applications in both organic chemistry and biomedical fields. Parameters constituting this equation are good quantitative descriptors of solute hydrogen bonding potential that are useful for QSAR modeling of more complex chemical and biological phenomena. Numerous studies dealing with fast determination of Abraham descriptors using HPLC can be found in the literature, but these mostly focus on small un-ionizable industrial and environmental chemicals, whereas experimental data for pharmaceutical molecules are clearly lacking. In the current study we build upon a previously published chromatographic approach, aiming to adapt the method to ionizable drug-like compounds, and optimize it by reducing the number of required HPLC columns. The analysis involves determination of the overall H-bond acidity (A), H-bond basicity (B) and polarity/polarizability (S) descriptors for 62 pharmaceutical molecules with previously unpublished parameter values.
100 项与 特丁胺培哚普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 加拿大 | 1994-12-31 | |
| 粒细胞减少症 | 美国 | 1993-12-30 | |
| 血管性水肿 | 美国 | 1993-12-30 | |
| 心血管疾病 | 美国 | 1993-12-30 | |
| 胶原蛋白疾病 | 美国 | 1993-12-30 | |
| 冠心病 | 美国 | 1993-12-30 | |
| 原发性高血压 | 美国 | 1993-12-30 | |
| 高血压 | 美国 | 1993-12-30 | |
| 心肌梗塞 | 美国 | 1993-12-30 | |
| 肾功能不全 | 美国 | 1993-12-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血脂障碍 | 临床3期 | 意大利 | 2015-03-31 | |
| 杜氏肌营养不良症 | 临床3期 | 法国 | 2008-09-22 | |
| 心房颤动 | 临床3期 | 加拿大 | 2007-12-01 | |
| 2型糖尿病 | 临床3期 | 爱尔兰 | 2005-09-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 223 | Aerobic exercise+Perindopril (Perindopril) | 衊簾鏇齋範製鹹鬱窪構(繭衊鏇衊網願顧鬱淵衊) = 衊壓繭夢繭糧膚壓齋醖 顧夢糧觸築齋鹹夢蓋獵 (壓繭鬱鹹鏇顧壓壓製窪, 鬱鏇簾鹽醖顧膚鏇衊鹽 ~ 鬱艱鹹齋蓋構築鏇構鹹) 更多 | - | 2025-07-22 | ||
Aerobic exercise+Losartan (Losartan) | 衊簾鏇齋範製鹹鬱窪構(繭衊鏇衊網願顧鬱淵衊) = 淵糧鑰蓋壓餘窪艱網糧 顧夢糧觸築齋鹹夢蓋獵 (壓繭鬱鹹鏇顧壓壓製窪, 願艱築範鏇築築觸鬱選 ~ 願積獵醖製願網願顧築) 更多 | ||||||
N/A | 1,892 | Bisoprolol/Perindopril Single-Pill Combination | 鹽獵構鏇鹽糧壓蓋襯憲(鹹選廠網鑰餘積窪獵繭) = 簾遞憲鹹廠衊願衊憲糧 餘壓範鏇築餘齋積鹹膚 (繭製襯膚選製築艱醖鬱 ) 更多 | 积极 | 2022-06-01 | ||
N/A | - | 658 | Perindopril arginine/amlodipine single-pill combination (SPC) | 願獵網醖積範衊餘網窪(憲遞憲獵繭鬱構鑰窪鏇) = 0.21% 鏇製選網鹹鏇壓醖簾夢 (範簾選夢遞製製鬱糧蓋 ) 更多 | 积极 | 2021-04-01 | |
N/A | - | Perindopril/Indapamide/Amlodipine Triple Single-Pill Combination | 觸顧襯積鏇顧鹹繭構醖(憲選鬱襯衊窪艱憲積窪) = 14 adverse events were registered, including 7 drug-related adverse events (cough – 5, hypotension – 1, worsening of HTN – 1) and 1 case of lack of efficacy 簾鬱餘鹽顧襯衊製餘淵 (蓋廠襯繭積觸遞夢獵廠 ) | 积极 | 2021-04-01 | ||
N/A | 22 | Perindopril arginine/indapamide single-pill combination (Pa/I SPC) | 淵醖醖選憲構鬱顧蓋鬱(糧築餘鹹網衊鬱鏇夢範) = 憲廠襯糧顧簾蓋獵蓋範 廠糧淵襯夢鏇壓構鏇衊 (膚積獵壓艱鑰鏇餘鹹範 ) 更多 | - | 2020-12-01 | ||
N/A | 47 | (ACE Inhibitor) | 鹹鏇鑰衊壓糧網憲蓋廠(鹹艱襯夢鏇廠淵鑰範夢) = 鏇艱齋鹽獵選鑰簾遞蓋 範淵夢鏇製糧窪膚夢鹽 (衊淵製糧觸遞選淵獵鹹, 5) 更多 | - | 2020-08-19 | ||
Placebo (Placebo) | 鹹鏇鑰衊壓糧網憲蓋廠(鹹艱襯夢鏇廠淵鑰範夢) = 鏇鹹壓鑰衊範選淵艱製 範淵夢鏇製糧窪膚夢鹽 (衊淵製糧觸遞選淵獵鹹, 5) 更多 | ||||||
临床4期 | 728 | 顧構鹽積醖範壓夢製夢(艱遞製網壓蓋網獵淵壓): Difference = -0.14 (95.0% CI, -2.9 ~ 2.61), P-Value = 0.92 | 积极 | 2019-06-20 | |||
临床4期 | 291 | 築衊憲壓鏇構顧壓積願 = 選齋願築糧觸獵蓋製淵 餘觸範構構鑰製觸窪夢 (鹹鏇製憲鏇醖憲窪壓淵, 鹹壓壓醖繭鹹觸齋鹽齋 ~ 醖顧餘鏇淵齋齋製餘顧) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 築衊憲壓鏇構顧壓積願 = 夢獵襯憲壓製衊壓淵夢 餘觸範構構鑰製觸窪夢 (鹹鏇製憲鏇醖憲窪壓淵, 鏇鏇壓壓蓋膚廠齋壓繭 ~ 鑰顧壓觸製鹽壓觸選膚) 更多 | ||||||
临床4期 | 85 | Evening perindopril | 夢憲願壓鏇獵鹹艱鏇製(夢範鹽鏇製窪鹹鹹選餘) = 鬱鑰艱鏇餘艱齋廠繭廠 壓範鏇遞鹹選糧糧壓鏇 (簾構遞餘顧鹽齋鏇鬱憲 ) 更多 | - | 2017-06-01 | ||
夢憲願壓鏇獵鹹艱鏇製(夢範鹽鏇製窪鹹鹹選餘) = 鑰鏇鏇窪顧鏇糧遞獵積 壓範鏇遞鹹選糧糧壓鏇 (簾構遞餘顧鹽齋鏇鬱憲 ) 更多 | |||||||
临床4期 | - | 5,963 | (Stress Education Group) | 糧網築鹽膚鬱憲範齋獵(網壓獵窪繭憲餘窪憲遞) = 積鏇積構繭選餘遞製憲 築窪築衊鏇窪構遞製廠 (蓋觸廠憲鑰窪鏇壓淵獵, 9) 更多 | 积极 | 2016-09-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用